Talphera Inc. Market Cap ($52.42 Million)
Market Cap & Net Worth: Talphera Inc. (TLPH)
Talphera Inc. market cap. Talphera Inc. (NASDAQ:TLPH) has a market capitalization of $52.42 Million ($52.42 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21530 globally and #4825 in its home market, demonstrating a -6.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Talphera Inc.'s stock price $1.01 by its total outstanding shares 51905796 (51.91 Million). Also see how efficiently does Talphera Inc. generate cash for how efficiently the company converts equity into cash flow.
Talphera Inc. Market Cap History (2015–2026)
Talphera Inc. market cap history from 2015 to 2026. Data shows change from $4.00 Billion to $52.42 Million (-32.12% CAGR). Check today's stock price for Talphera Inc. for real-time trading data and today's change.
Index Memberships
Talphera Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #611 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2040 of 3165 |
Weight: Talphera Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Talphera Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Talphera Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Talphera Inc. net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2113.31x
Talphera Inc.'s market cap is 2113.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.70 Billion | $17.36 Million | -$43.16 Million | 155.51x | N/A |
| 2017 | $2.11 Billion | $8.00 Million | -$51.51 Million | 263.59x | N/A |
| 2018 | $2.40 Billion | $2.15 Million | -$47.15 Million | 1114.85x | N/A |
| 2019 | $2.19 Billion | $2.29 Million | -$53.24 Million | 956.94x | N/A |
| 2020 | $1.29 Billion | $5.42 Million | -$40.38 Million | 237.68x | N/A |
| 2021 | $581.34 Million | $378.00K | -$35.10 Million | 1537.95x | N/A |
| 2022 | $117.31 Million | $1.77 Million | $42.52 Million | 66.24x | 2.76x |
| 2023 | $38.41 Million | $651.00K | -$18.40 Million | 59.00x | N/A |
| 2025 | $59.17 Million | $28.00K | -$14.29 Million | 2113.31x | N/A |
Competitor Companies of TLPH by Market Capitalization
Companies near Talphera Inc. in the global market cap rankings as of November 4, 2026. Also see how large is Talphera Inc.'s balance sheet for a full breakdown of the balance sheet.
Key companies related to Talphera Inc. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Talphera Inc. (2015–2026)
Market capitalization of Talphera Inc. from 2015 to today. Between 2015 and today, Talphera Inc.'s market cap moved from $4.00 Billion to $ 52.42 Million, with a yearly change of -32.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $52.42 Million | -11.40% |
| 2025 | $59.17 Million | +117.14% |
| 2024 | $27.25 Million | -29.05% |
| 2023 | $38.41 Million | -67.26% |
| 2022 | $117.31 Million | -79.82% |
| 2021 | $581.34 Million | -54.84% |
| 2020 | $1.29 Billion | -41.23% |
| 2019 | $2.19 Billion | -8.66% |
| 2018 | $2.40 Billion | +13.79% |
| 2017 | $2.11 Billion | -21.92% |
| 2016 | $2.70 Billion | -32.47% |
| 2015 | $4.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Talphera Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.42 Million USD |
| MoneyControl | $52.42 Million USD |
| MarketWatch | $52.42 Million USD |
| marketcap.company | $52.42 Million USD |
| Reuters | $52.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more